DartCF: The Dartmouth Cystic Fibrosis Research Center
DartCF:达特茅斯囊性纤维化研究中心
基本信息
- 批准号:10895148
- 负责人:
- 金额:$ 4.22万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAddressAffectAntibioticsArchivesAreaAwardBasic ScienceBioinformaticsBiologyBiostatistics CoreCessation of lifeChronicClinicalClinical ResearchCoculture TechniquesCollaborationsCommunitiesComplexCoupledCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDataData ScienceData SetDatabasesDevelopmentDiabetes MellitusDiseaseEcologyEducational workshopEndowmentEpitheliumEvaluationExtramural ActivitiesFacultyFosteringFoundationsFunctional disorderFundingGenetic DiseasesGoalsImmuneImmune responseImmunityInflammatory ResponseInstitutionInterventionInvestigationLiver diseasesLongevityLungMalnutritionMediatingMetabolicMicrobeMiningMissionModelingMonitorMutationNational Institute of Diabetes and Digestive and Kidney DiseasesOrganOutcomePancreatitisPathogenesisPatientsPharmaceutical PreparationsPilot ProjectsPreclinical Drug DevelopmentQuality of lifeResearchResearch PersonnelResourcesRespiratory Tract InfectionsServicesSignal TransductionStructureSymptomsSystemTherapeuticTissuesTrainingTranslational ResearchVirulenceWorkantimicrobialbasebody systemcareer developmentcohortcommensal microbescommunity centercomplex datacystic fibrosis patientscystic fibrosis related diabetesdata submissiondysbiosisforginggastrointestinalgut dysbiosisgut microbeshost-microbe interactionsimprovedimproved outcomeinnovationinsightinterestinteroperabilitymembermicrobialmicrobial communitymicrobiomenovelnovel strategiesnovel therapeutic interventionnovel therapeuticsopen datapathogenic microbepre-clinicalprematureprogramsrecruitsynergismsystemic inflammatory responsetooltranslational study
项目摘要
In cystic fibrosis (CF), mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) unleash a
cascade of clinical disorders, including chronic airway infections, systemic inflammation, microbial virulence,
diabetes, malnutrition and liver disease. Great progress has been made in some areas of disease, and CFTR
modulators provide dramatic benefits to some patients. Still, there is growing evidence of the interconnections
among lung and gut dysbiosis and CF pathogenesis. As patients live longer, formerly rare symptoms are
becoming more common. Thus, there is a pressing need to both understand and systematically treat the
functional relationships between CFTR function, commensal and pathogenic microbes, metabolic states, and
innate and acquired immune responses. Dartmouth has an interactive CF research team of 49 faculty members
with extramural funding of $11.1M/year, studying epithelial biology, CFTR correction, host-microbe interactions,
gut dysbiosis and immunity, as well as airway infections and antimicrobial strategies. The Dartmouth CF
Research Center (DartCF) will build on progress made in the past year. We will deploy P30 and institutional
funds to recruit new CF faculty, strengthen our research base, and foster interdisciplinary discovery. Our aims
are: 1) to catalyze new research in CF basic and translational research in areas of interest to NIDDK; 2) to
develop integrative strategies to understand and address CF pathobiology; 3) to create new research tools and
support CF research through outstanding shared services; and 4) to build research capacity in CF locally,
regionally, and nationally. We will focus P30 resources on 1) pioneering transparency and interoperability for CF
datasets, 2) forging collaborations between CF and data-science researchers to mine these datasets for
systems-level perspectives and 3) building on unique Dartmouth longitudinal patient cohorts to explore microbial
community structure in the gut, host-microbe signaling, the effects of existing therapies, and implications for
whole-body disease. A key theme is that dysbioses are interconnected, and that parallel investigations, coupled
by powerful new data-science strategies can understand this complex underlying biology and reveal new
therapeutic approaches. In parallel, we will leverage our research base to support early-stage preclinical target
development. DartCF supports a variety of mechanisms. First, we fund a Pilot Project Project (P3) to develop
new scientific opportunities in NIDDK-revelant areas and to recruit new faculty members to the Center. Second,
we fund three scientific cores to support studies in CF: a Gastrointestinal Biology Core (GIBC), a Clinical and
Translational Research Core (CTRC), and a CF Bioinformatics & Biostatistics Core (CF-BBC). Finally, we
support an Enrichment and Research Administration Core (ERAC) to foster an interactive scientific community,
sponsor retreats and courses, and track program progress. These efforts will identify new CF therapeutic
opportunities, develop novel interventions, monitor the resulting changes body-wide, and track outcomes.
DartCF will intensify the translation of research into improved CF outcomes at Dartmouth.
在囊性纤维化 (CF) 中,囊性纤维化跨膜电导调节因子 (CFTR) 的突变会释放出
一系列临床疾病,包括慢性气道感染、全身炎症、微生物毒力、
糖尿病、营养不良和肝病。一些疾病领域取得了巨大进展,CFTR
调节剂为一些患者带来了巨大的好处。尽管如此,越来越多的证据表明它们之间存在相互联系
肺和肠道菌群失调与 CF 发病机制之间的关系。随着患者寿命的延长,以前罕见的症状也变得更加常见。
变得越来越普遍。因此,迫切需要了解并系统地治疗
CFTR 功能、共生微生物和病原微生物、代谢状态和
先天性和获得性免疫反应。达特茅斯拥有一支由 49 名教职人员组成的互动 CF 研究团队
每年提供 1110 万美元的外部资金,研究上皮生物学、CFTR 校正、宿主-微生物相互作用、
肠道菌群失调和免疫力,以及气道感染和抗菌策略。达特茅斯CF
研究中心(DartCF)将在过去一年取得的进展的基础上再接再厉。我们将部署P30和机构
资金用于招募新的 CF 教师、加强我们的研究基础并促进跨学科发现。我们的目标
是: 1) 促进 NIDDK 感兴趣领域的 CF 基础研究和转化研究的新研究; 2)到
制定综合策略来理解和解决 CF 病理学问题; 3)创建新的研究工具
通过出色的共享服务支持 CF 研究; 4) 建设本地 CF 研究能力,
区域性和全国性。我们将把 P30 资源集中在 1) 开创 CF 的透明度和互操作性
数据集,2)在 CF 和数据科学研究人员之间建立合作,挖掘这些数据集
系统级视角和 3) 以独特的达特茅斯纵向患者队列为基础来探索微生物
肠道中的群落结构、宿主微生物信号传导、现有疗法的效果以及对
全身疾病。一个关键主题是生态失调是相互关联的,并且平行的研究,耦合
通过强大的新数据科学策略可以理解这种复杂的基础生物学并揭示新的
治疗方法。与此同时,我们将利用我们的研究基础来支持早期临床前目标
发展。 DartCF 支持多种机制。首先,我们资助一个试点项目(P3)来开发
NIDDK 相关领域的新科学机会,并为该中心招募新的教职人员。第二,
我们资助三个科学核心来支持 CF 研究:胃肠生物学核心 (GIBC)、临床和
转化研究核心 (CTRC) 和 CF 生物信息学与生物统计学核心 (CF-BBC)。最后,我们
支持浓缩和研究管理核心(ERAC)以培育互动的科学界,
赞助静修会和课程,并跟踪计划进度。这些努力将确定新的 CF 治疗方法
机会,制定新颖的干预措施,监测由此产生的全身变化,并跟踪结果。
DartCF 将加强研究成果的转化,以改善达特茅斯的 CF 结果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DEAN R MADDEN其他文献
DEAN R MADDEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DEAN R MADDEN', 18)}}的其他基金
DartCF: The Dartmouth Cystic Fibrosis Research Center
DartCF:达特茅斯囊性纤维化研究中心
- 批准号:
10686303 - 财政年份:2018
- 资助金额:
$ 4.22万 - 项目类别:
DartCF: The Dartmouth Cystic Fibrosis Research Center
DartCF:达特茅斯囊性纤维化研究中心
- 批准号:
10895149 - 财政年份:2018
- 资助金额:
$ 4.22万 - 项目类别:
DartCF: The Dartmouth Cystic Fibrosis Research Center
DartCF:达特茅斯囊性纤维化研究中心
- 批准号:
10001759 - 财政年份:2018
- 资助金额:
$ 4.22万 - 项目类别:
DartCF: The Dartmouth Cystic Fibrosis Research Center
DartCF:达特茅斯囊性纤维化研究中心
- 批准号:
10678819 - 财政年份:2018
- 资助金额:
$ 4.22万 - 项目类别:
DartCF: The Dartmouth Cystic Fibrosis Research Center
DartCF:达特茅斯囊性纤维化研究中心
- 批准号:
10474845 - 财政年份:2018
- 资助金额:
$ 4.22万 - 项目类别:
DartCF: The Dartmouth Cystic Fibrosis Research Center
DartCF:达特茅斯囊性纤维化研究中心
- 批准号:
10240591 - 财政年份:2018
- 资助金额:
$ 4.22万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 4.22万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 4.22万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 4.22万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 4.22万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 4.22万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 4.22万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 4.22万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 4.22万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 4.22万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 4.22万 - 项目类别:
Research Grant